Services on Demand
Journal
Article
Indicators
- Cited by SciELO
Related links
- Similars in SciELO
Share
Medicina (Buenos Aires)
Print version ISSN 0025-7680On-line version ISSN 1669-9106
Abstract
FUCHS, Alicia G.. Treatment and post-treatment with lonidamine in human colon carcinoma HT-29 cell line. Medicina (B. Aires) [online]. 2008, vol.68, n.1, pp.13-22. ISSN 0025-7680.
Lonidamine (1-[ 2,4-dichlorophenyl methyl]-1H indazole-3-carboxylic acid), lnd, is an antitumoral drug acting on mitochondria and glucose metabolism. Cell growth and metabolic effects of lnd and drug post-treatment effect were investigated in undifferentiated HT-29 human colonic carcinoma cell line which requires high glucose medium concentration for growth. 0.2 mM lnd significantly decreased cell spreading and growth in monolayer or agar cell culture. After drug treatment cell growth was reestablished to control value within 24 h. Ind modified glycoconjugates and mannose-receptor distribution (analyzed by confocal microscopy), while glucose-glycogen and protein synthesis were not affected, these being the possible reasons for the fast reversible effect.
Keywords : Colonic carcinoma; Lonidamine; Cell growth.